Aurinia Pharmaceuticals Inc (AUPH) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Aurinia Pharmaceuticals Inc   (NASDAQ: AUPH)
 

Aurinia Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information





AUPH Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 18.87 % 12.24 % 9.19 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 7.1 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 19.76 % 9.25 % 7.99 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 4.43 % 2.69 % 2.09 % 2.61 %
Revenue 5 Year Average Growth 41.38 % 7.41 % 8.65 % 10.59 %


AUPH's Growth Comparisons in II. Quarter 2026




Aurinia Pharmaceuticals Inc 's 18.87% year on year Revenue growth, has slowed-down in the second quarter 2026 to 83 millions, but outperforms the 12.24% rise in the Major Pharmaceutical Preparations industry, and 9.19% growth in the Healthcare sector. Comparing the second quarter sales growth, both Major Pharmaceutical Preparations industry and Aurinia Pharmaceuticals Inc outperformed 10.9% overall market increase.

Comparing the company's Revenue to the first quarter results, sales were higher by 7.1% . On the yearly basis, average annual sales growth for Aurinia Pharmaceuticals Inc is 41.38%, while S & P 500's including only Businesses with the second quarter 2026 earnings, average annual sales growth is 10.59% over the past five years.

AUPH Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product
-
-
License, Collaboration and Royalty Revenue
-
-
Service
-
-
Total
18.87 %
7.1 %


Growth Rates of AUPH's Income in the second quarter 2026


AUPH Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) 130.75 % -8.69 % 5.13 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) 11.88 % -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) 189.85 % 30.72 % 30.96 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) 21.09 % -2.28 % 4.91 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) 73.91 % -34.78 % -25.81 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) 8.9 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) 418.03 % 6.22 % 9.85 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 5.33 % -10.03 % -4.69 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

AUPH Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) 73.91 % -35.13 % -26.29 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) 8.9 % 2.8 % -0.86 % 27.07 %
Y / Y Net Income Change (Q2 TTM) 418.03 % 5.2 % 15.48 % 57.33 %
Sequential Net Income Change (Q2 TTM) 5.33 % -10.18 % -6.71 % 18.65 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

AUPH's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) 81.25 % -40.16 % -25.81 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) 11.54 % -7.73 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) 436.36 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) 5.83 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.79 % 0.17 % -28.52 %



AUPH EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) 75 % -40.49 % -26.29 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) 12 % -2.61 % -0.86 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) 5.56 % -7.05 % -4.12 % 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Aurinia Pharmaceuticals Inc showed impressive 75% year on year rise in the second quarter to $0.28, despite the -40.49% inMajor Pharmaceutical Preparations industry, Healthcare sector dropped -26.29%. Slow second quarter 2026 income per share, in Major Pharmaceutical Preparations industry and Healthcare sector, were portrayed in the Aurinia Pharmaceuticals Inc results which underperformed overall market.

The bottom-line improved by 12% from the first quarter. Looking into annual income per share rise of 41.38%, and S & P 500's average yearly income per share growth is 22.96% over the five years, including only Businesses with the second quarter 2026 earnings reports. Aurinia Pharmaceuticals Inc grew faster than the market.

AUPH Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 18.9 % 25.53 % 48.48 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) 61.4 % -42.35 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 89.41 % 12.28 % 19.59 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 5.01 % 3.34 % 5.76 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -20.41 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 100 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) -15.33 % 16.46 % 7.77 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) -7.3 % 2.81 % 1.52 % 23.05 %
Capital Expenditures 5 Year Avg. Change - 7.84 % 8.61 % 14.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.